We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+48.38%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
+$389M
Cap. Flow
-$37.2M
Cap. Flow %
-2.11%
Top 10 Hldgs %
60.65%
Holding
62
New
13
Increased
10
Reduced
5
Closed
11

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$53M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$51.2M
3
SAGE
Sage Therapeutics
SAGE
+$43.1M
4
ANAB icon
AnaptysBio
ANAB
+$30.7M
5
IMMU
Immunomedics Inc
IMMU
+$26.5M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$160M
2
AMRN
Amarin Corp
AMRN
+$53.1M
3
PTCT icon
PTC Therapeutics
PTCT
+$33.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.8M
5
SLDB icon
Solid Biosciences
SLDB
+$21.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$221M 12.5%
1,715,560
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$179M 10.11%
8,450,000
+1,500,000
+22% +$26.5M
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$153M 8.67%
925,000
– –
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$109M 6.17%
3,363,377
– –
MDCO
5
DELISTED
Medicines Co
MDCO
$82.1M 4.65%
967,000
+217,000
+29% +$14.5M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$79.9M 4.52%
2,075,905
– –
DBVT
7
DBV Technologies
DBVT
$799M
$68.3M 3.86%
638,460
+108,460
+20% +$8.68M
ALLK
8
DELISTED
Allakos
ALLK
$64.4M 3.64%
675,000
– –
ESPR
9
DELISTED
Esperion Therapeutics
ESPR
$58.1M 3.29%
975,000
– –
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$57.1M 3.23%
+500,000
New +$53M
QURE icon
11
uniQure
QURE
$3.03B
$54.8M 3.1%
765,400
-100,000
-12% -$5.49M
LABD icon
12
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$35.6M 2.02%
+14,425
New +$51.2M
GOSS icon
13
Gossamer Bio
GOSS
$82.9M
$34.2M 1.93%
2,185,000
+110,000
+5% +$2.22M
RCKT icon
14
Rocket Pharmaceuticals
RCKT
$340M
$33.4M 1.89%
1,466,051
– –
ARGX icon
15
argenx
ARGX
$53.4B
$32.1M 1.82%
200,000
– –
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.57B
$29M 1.64%
225,000
-325,000
-59% -$32.8M
KDMN
17
DELISTED
Kadmon Holdings, Inc.
KDMN
$28.1M 1.59%
6,205,882
+2,205,882
+55% +$8.07M
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$26.8M 1.52%
1,733,583
– –
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$25.3M 1.43%
+350,000
New +$43.1M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$24.5M 1.39%
800,000
+100,000
+14% +$2.77M
MTNB icon
21
Matinas BioPharma
MTNB
$1.88M
$23.1M 1.31%
203,766
– –
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$22.6M 1.28%
2,325,000
– –
CABA icon
23
Cabaletta Bio
CABA
$437M
$21.9M 1.24%
+1,566,361
New +$18.6M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$11.6B
$21.1M 1.2%
250,000
-200,000
-44% -$15.1M
ANAB icon
25
AnaptysBio
ANAB
$1.58B
$21.1M 1.19%
+1,300,000
New +$30.7M
1
2 3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Boxer Capital held 62 positions worth $1.77B, up 28% from $1.38B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Boxer Capital's Q4 2019 filing shows 13 new, 10 increased, 5 reduced and 11 closed positions. Its largest new stake was Seagen Inc. Common Stock: 500,000 shares worth $57.1M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $160M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 78% a quarter earlier.

  • Boxer Capital's largest Q4 2019 buy was Seagen Inc. Common Stock: 500,000 shares worth $57.1M.
  • Boxer Capital added most to Immunomedics Inc in Q4 2019, an estimated $26.5M increase.
  • Boxer Capital's biggest Q4 2019 reduction was Sarepta Therapeutics, cutting an estimated $32.8M.
  • Boxer Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $160M.
  • Boxer Capital's ten largest holdings make up 61% of its $1.77B portfolio in Q4 2019.
  • Boxer Capital opened 13 new positions and closed 11 in Q4 2019.
  • Boxer Capital's portfolio value rose 28% quarter-over-quarter to $1.77B.

Based on Boxer Capital's 13F filing for Q4 2019, filed 14 Feb 2020.